Tejaswini Kulkarni

Tejaswini Kulkarni practices at University of Alabama Birmingham Hospital in Birmingham, Alabama.

Tejaswini Kulkarni's NPI, 1043531593, was assigned on June 18, 2010. Tejaswini Kulkarni holds Alabama license 32618.

Tejaswini Kulkarni's primary practice is University of Alabama Birmingham Hospital, at 619 19th S St, Birmingham, AL 35211 in Jefferson County. The practice phone is (205) 731-9770.

Tejaswini Kulkarni's primary practice is University of Alabama Birmingham Hospital in Birmingham, Alabama. Tejaswini Kulkarni is also affiliated with UAB Hospital. The medical group on file is UAB Medicine.

Dmand AI tracks the electronic health record (EHR) system at each site where Tejaswini Kulkarni practices. Vendor and product names are available with a free account.

Pulmonary disease is Tejaswini Kulkarni's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Tejaswini Kulkarni is licensed in Alabama.

CMS data shows 184 Medicare services from Tejaswini Kulkarni across 5 procedure codes in 2024, for 117 Medicare patients. Medicare paid $15,550 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 117 Medicare patients who saw Tejaswini Kulkarni in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Tejaswini Kulkarni's median patient age at 71, with 50% women.

In 2024, Tejaswini Kulkarni wrote 181 Medicare Part D claims for 76 patients. 63% of them were for generic drugs. CMS names the drug for 120 of them, across 5 drugs with 11 or more claims each, at $678,946 in total drug cost. In 2023, CMS named 132 claims across 3 drugs.

Tejaswini Kulkarni accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 41 papers to Tejaswini Kulkarni, published from 2015 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Idiopathic Pulmonary Fibrosis, Lung and Mice, Inbred C57BL. Tejaswini Kulkarni has published most often in Am J Physiol Lung Cell Mol Physiol. Tejaswini Kulkarni's most frequent co-authors are Victor Thannickal, Veena B. Antony, MD and Tracy Renee Luckhardt.

Dmand AI links Tejaswini Kulkarni to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Idiopathic Pulmonary Fibrosis, Post-Acute COVID-19 Syndrome and Post-Infectious Disorders. Open Payments lists research payments to Tejaswini Kulkarni that name 3 trials.

CMS Open Payments shows 207 general payments to Tejaswini Kulkarni from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $89,520. It also lists 26 research payments totaling $23,864 from 2022 to 2025, naming 3 clinical trials.